前列腺癌放射性药物治疗的临床前开发
本文综述前列腺癌放射性药物治疗的临床前开发进展,涵盖治疗用放射性核素与肿瘤靶向分子两大主题。放射性药物治疗在转移性去势抵抗性疾病中显示显著成功,PSMA是临床前文献中研究最充分的前列腺癌相关蛋白酶。当前临床前实验聚焦于177Lu-PSMA-617及研究性药物的结构修饰,以提高肿瘤靶向并减少脱靶结合与健康器官毒性。
要点
- PSMA是临床前文献中研究最充分的前列腺癌相关蛋白酶,基于高亲和力抗体和小分子的PSMA靶向药物正在研究中。
- 177Lu仍是最广泛使用的放射性核素,α粒子发射体和多种放射性金属及放射性卤素被作为潜在替代方案评估。
- 机制驱动的联合治疗似乎是临床前前列腺癌放射性治疗的新兴领域。
核心结论
- 本文综述前列腺癌放射性药物治疗的临床前开发现状,按治疗用放射性核素与肿瘤靶向方法两大主题总结。
- 近期177Lu标记低分子量药物177Lu-PSMA-617的监管批准是一项重大成就。
- 当前临床前实验聚焦于177Lu-PSMA-617及相关研究性药物的结构修饰,以提高肿瘤靶向并减少脱靶结合与健康器官毒性。
研究设计与样本
- 本文为综述,总结与前列腺癌临床前放射性药物治疗相关的当前进展,分为治疗用放射性核素和肿瘤靶向方法两大主题。
主要发现
- 临床前前列腺癌研究中使用的治疗用放射性核素主要为发射α粒子、β-粒子或俄歇电子的放射性金属或放射性卤素。
- 单克隆抗体、抗体衍生片段、肽和小分子常被用作肿瘤靶向分子。
- PSMA是临床前文献中研究最充分的前列腺癌相关蛋白酶,PSMA靶向放射性治疗药物正用高亲和力抗体和小分子药物进行安全性和有效性研究。
- 早期几代药物仅通过将显像剂的放射性核素替换为治疗用核素而开发,后期进行了广泛的构效关系研究以解决初始患者数据中的安全性和有效性问题。
- 除PSMA外,其他前列腺癌相关蛋白酶如人激肽释放酶肽酶(HK2和HK3)已用单克隆抗体靶向平台探索,靶向DLL-3、CD46和CDCP1等受体的单克隆抗体也已开发用于放射性药物治疗。
关键数值与推荐
- 177Lu仍是最广泛使用的放射性核素,近年来碘-131(128I)、钇-90(89Y)、铜-67(67Cu)和铽-161(161Tb)标记的类似物被评估为潜在替代方案。
- 携带α粒子发射放射性卤素砹-211(211At)或放射性金属锕-225(225Ac)、铅-212(212Pb)、镭-223(223Ra)和钍-227(227Th)的药物在临床前研究中得到越来越多研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer is a leading cause of cancer death in men worldwide. Among the various treatment options, radiopharmaceutical therapy has shown notable success in metastatic, castration-resistant disease. Radiopharmaceutical therapy is a systemic approach that delivers cytotoxic radiation doses precisely to the malignant tumors and/or tumor microenvironment. Therapeutic radiopharmaceuticals are composed of a therapeutic radionuclide and a high-affinity, tumor-targeting carrier molecule. Therapeutic radionuclides used in preclinical prostate cancer studies are primarily α-, β--, or Auger-electron-emitting radiometals or radiohalogens. Monoclonal antibodies, antibody-derived fragments, peptides, and small molecules are frequently used as tumor-targeting molecules. Over the years, several important membrane-associated proteases and receptors have been identified, validated, and subsequently used for preclinical radiotherapeutic development for prostate cancer. Prostate-specific membrane antigen (PSMA) is the most well-studied prostate cancer-associated protease in preclinical literature. PSMA-targeting radiotherapeutic agents are being investigated using high-affinity antibody- and small-molecule-based agents for safety and efficacy. Early generations of such agents were developed simply by replacing radionuclides of the imaging agents with therapeutic ones. Later, extensive structure-activity relationship studies were conducted to address the safety and efficacy issues obtained from initial patient data. Recent regulatory approval of the 177Lu-labeled low-molecular-weight agent, 177Lu-PSMA-617, is a significant accomplishment. Current preclinical experiments are focused on the structural modification of 177Lu-PSMA-617 and relevant investigational agents to increase tumor targeting and reduce off-target binding and toxicity in healthy organs. While lutetium-177 (177Lu) remains the most widely used radionuclide, radiolabeled analogs with iodine-131 (128I), yttrium-90 (89Y), copper-67 (67Cu), and terbium-161 (161Tb) have been evaluated as potential alternatives in recent years. In addition, agents carrying the α-particle-emitting radiohalogen, astatine-211 (211At), or radiometals, actinium-225 (225Ac), lead-212 (212Pb), radium-223 (223Ra), and thorium-227 (227Th), have been increasingly investigated in preclinical research. Besides PSMA-based radiotherapeutics, other prominent prostate cancer-related proteases, for example, human kallikrein peptidases (HK2 and HK3), have been explored using monoclonal-antibody-(mAb)-based targeting platforms. Several promising mAbs targeting receptors overexpressed on the different stages of prostate cancer have also been developed for radiopharmaceutical therapy, for example, Delta-like ligand 3 (DLL-3), CD46, and CUB domain-containing protein 1 (CDCP1). Progress is also being made using peptide-based targeting platforms for the gastrin-releasing peptide receptor (GRPR), a well-established membrane-associated receptor expressed in localized and metastatic prostate cancers. Furthermore, mechanism-driven combination therapies appear to be a burgeoning area in the context of preclinical prostate cancer radiotherapeutics. Here, we review the current developments related to the preclinical radiopharmaceutical therapy of prostate cancer. These are summarized in two major topics: (1) therapeutic radionuclides and (2) tumor-targeting approaches using monoclonal antibodies, small molecules, and peptides.
引用
- Alati S, Singh R, Pomper MG, et al. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer. Semin Nucl Med. 2023. PMID: 37468417. doi:10.1053/j.semnuclmed.2023.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。